These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

328 related articles for article (PubMed ID: 22076043)

  • 1. Chemovirotherapy for head and neck squamous cell carcinoma with EGFR-targeted and CD/UPRT-armed oncolytic measles virus.
    Zaoui K; Bossow S; Grossardt C; Leber MF; Springfeld C; Plinkert PK; Kalle Cv; Ungerechts G
    Cancer Gene Ther; 2012 Mar; 19(3):181-91. PubMed ID: 22076043
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-Tumor Effects of MAPK-Dependent Tumor-Selective Oncolytic Vaccinia Virus Armed with CD/UPRT against Pancreatic Ductal Adenocarcinoma in Mice.
    Kurosaki H; Nakatake M; Sakamoto T; Kuwano N; Yamane M; Ishii K; Fujiwara Y; Nakamura T
    Cells; 2021 Apr; 10(5):. PubMed ID: 33922406
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chemovirotherapy of malignant melanoma with a targeted and armed oncolytic measles virus.
    Kaufmann JK; Bossow S; Grossardt C; Sawall S; Kupsch J; Erbs P; Hassel JC; von Kalle C; Enk AH; Nettelbeck DM; Ungerechts G
    J Invest Dermatol; 2013 Apr; 133(4):1034-42. PubMed ID: 23223133
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enhanced killing of ovarian carcinoma using oncolytic measles vaccine virus armed with a yeast cytosine deaminase and uracil phosphoribosyltransferase.
    Hartkopf AD; Bossow S; Lampe J; Zimmermann M; Taran FA; Wallwiener D; Fehm T; Bitzer M; Lauer UM
    Gynecol Oncol; 2013 Aug; 130(2):362-8. PubMed ID: 23676551
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The oncolytic effect of recombinant vesicular stomatitis virus is enhanced by expression of the fusion cytosine deaminase/uracil phosphoribosyltransferase suicide gene.
    Porosnicu M; Mian A; Barber GN
    Cancer Res; 2003 Dec; 63(23):8366-76. PubMed ID: 14678998
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination of a fusogenic glycoprotein, prodrug activation, and oncolytic herpes simplex virus for enhanced local tumor control.
    Simpson GR; Han Z; Liu B; Wang Y; Campbell G; Coffin RS
    Cancer Res; 2006 May; 66(9):4835-42. PubMed ID: 16651439
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeted chemotherapy for head and neck cancer with a chimeric oncolytic adenovirus coding for bifunctional suicide protein FCU1.
    Dias JD; Liikanen I; Guse K; Foloppe J; Sloniecka M; Diaconu I; Rantanen V; Eriksson M; Hakkarainen T; Lusky M; Erbs P; Escutenaire S; Kanerva A; Pesonen S; Cerullo V; Hemminki A
    Clin Cancer Res; 2010 May; 16(9):2540-9. PubMed ID: 20388844
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oncolytic herpes simplex virus expressing yeast cytosine deaminase: relationship between viral replication, transgene expression, prodrug bioactivation.
    Yamada S; Kuroda T; Fuchs BC; He X; Supko JG; Schmitt A; McGinn CM; Lanuti M; Tanabe KK
    Cancer Gene Ther; 2012 Mar; 19(3):160-70. PubMed ID: 22076044
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pulsed versus continuous application of the prodrug 5-fluorocytosine to enhance the oncolytic effectiveness of a measles vaccine virus armed with a suicide gene.
    Yurttas C; Berchtold S; Malek NP; Bitzer M; Lauer UM
    Hum Gene Ther Clin Dev; 2014 Jun; 25(2):85-96. PubMed ID: 24933569
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Suicide gene therapy with the yeast fusion gene cytosine deaminase/uracil phosphoribosyltransferase is not enough for pancreatic cancer.
    Fogar P; Navaglia F; Basso D; Greco E; Zambon CF; Fadi E; Falda A; Stranges A; Vannozzi F; Danesi R; Pedrazzoli S; Plebani M
    Pancreas; 2007 Oct; 35(3):224-31. PubMed ID: 17895842
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics and the bystander effect in CD::UPRT/5-FC bi-gene therapy of glioma.
    Shi DZ; Hu WX; Li LX; Chen G; Wei D; Gu PY
    Chin Med J (Engl); 2009 Jun; 122(11):1267-72. PubMed ID: 19567135
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined treatment, based on lysomustine administration with mesenchymal stem cells expressing cytosine deaminase therapy, leads to pronounced murine Lewis lung carcinoma growth inhibition.
    Krassikova LS; Karshieva SS; Cheglakov IB; Belyavsky AV
    J Gene Med; 2016 Sep; 18(9):220-33. PubMed ID: 27461566
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intrinsic properties of tumour cells have a key impact on the bystander effect mediated by genetically engineered mesenchymal stromal cells.
    Matuskova M; Baranovicova L; Kozovska Z; Durinikova E; Pastorakova A; Hunakova L; Waczulikova I; Nencka R; Kucerova L
    J Gene Med; 2012 Dec; 14(12):776-87. PubMed ID: 23150190
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oncolysis using herpes simplex virus type 1 engineered to express cytosine deaminase and a fusogenic glycoprotein for head and neck squamous cell carcinoma.
    Price DL; Lin SF; Han Z; Simpson G; Coffin RS; Wong J; Li S; Fong Y; Wong RJ
    Arch Otolaryngol Head Neck Surg; 2010 Feb; 136(2):151-8. PubMed ID: 20157061
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epidermal growth factor receptor variant III in head and neck squamous cell carcinoma is not relevant for targeted therapy and irradiation.
    Thomas Koch D; Pickhard A; Gebel L; Buchberger AMS; Bas M; Mogler C; Reiter R; Piontek G; Wirth M
    Oncotarget; 2017 May; 8(20):32668-32682. PubMed ID: 28427242
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The use of 19F spectroscopy and diffusion-weighted MRI to evaluate differences in gene-dependent enzyme prodrug therapies.
    Hamstra DA; Lee KC; Tychewicz JM; Schepkin VD; Moffat BA; Chen M; Dornfeld KJ; Lawrence TS; Chenevert TL; Ross BD; Gelovani JT; Rehemtulla A
    Mol Ther; 2004 Nov; 10(5):916-28. PubMed ID: 15509509
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined suicide gene therapy for human colon cancer cells using adenovirus-mediated transfer of escherichia coli cytosine deaminase gene and Escherichia coli uracil phosphoribosyltransferase gene with 5-fluorocytosine.
    Koyama F; Sawada H; Hirao T; Fujii H; Hamada H; Nakano H
    Cancer Gene Ther; 2000 Jul; 7(7):1015-22. PubMed ID: 10917204
    [TBL] [Abstract][Full Text] [Related]  

  • 18. FGFR3-TACC3 fusion proteins act as naturally occurring drivers of tumor resistance by functionally substituting for EGFR/ERK signaling.
    Daly C; Castanaro C; Zhang W; Zhang Q; Wei Y; Ni M; Young TM; Zhang L; Burova E; Thurston G
    Oncogene; 2017 Jan; 36(4):471-481. PubMed ID: 27345413
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vivo gene therapy for colon cancer using adenovirus-mediated, transfer of the fusion gene cytosine deaminase and uracil phosphoribosyltransferase.
    Chung-Faye GA; Chen MJ; Green NK; Burton A; Anderson D; Mautner V; Searle PF; Kerr DJ
    Gene Ther; 2001 Oct; 8(20):1547-54. PubMed ID: 11704815
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hedgehog signaling alters reliance on EGF receptor signaling and mediates anti-EGFR therapeutic resistance in head and neck cancer.
    Keysar SB; Le PN; Anderson RT; Morton JJ; Bowles DW; Paylor JJ; Vogler BW; Thorburn J; Fernandez P; Glogowska MJ; Takimoto SM; Sehrt DB; Gan GN; Eagles-Soukup JR; Serracino H; Hirsch FR; Lucia MS; Thorburn A; Song JI; Wang XJ; Jimeno A
    Cancer Res; 2013 Jun; 73(11):3381-92. PubMed ID: 23576557
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.